LEO Pharma

LEO Pharma announces annual results 2021

Share
A year of investments and transformation of the global organization, progressing on strategy towards 2030

Growth in net sales

Net sales grew 5% to DKK 9,957 million when excluding discontinued and divested products. Strategic psoriasis products Enstilar® and Kyntheum® continued to grow and gain market shares.

-          Sales of Kyntheum® outperformed market growth rates in biologics for psoriasis growing 32% to DKK 615 million.

-          Revenue of Enstilar® grew 15% to DKK 1,292 million.

-          Products in our Eczema/Skin infection range grew 6% to DKK 2,819 million.

-          Revenue for Eczema grew 14%, driven by both Protopic® and our Advantan® portfolio growing by 11% and 12%, respectively.

Operating loss higher than financial guidance

EBIT: Operating loss of DKK 4,156 million, higher than financial guidance due to continued investments in R&D and launch of tralokinumab, delay of Adbry™ (US tralokinumab brand name) approval in the US, write-off of patidegib and introduction of long-term efficiencies.

-          23% of revenues invested in R&D

-          Write-off of patidegib amounts to DKK 435 million

Significant advancement in R&D pipeline in line with 2030 strategy

LEO Pharma’s R&D pipeline progressed significantly and achieved important milestones to support future growth.

-          EMA and FDA approval of tralokinumab in atopic dermatitis

-          Delgocitinib, a topical pan-JAK inhibitor for treatment of chronic hand eczema progressed to phase 3

-          Anti IL-22R, an anti-inflammatory monoclonal antibody for atopic dermatitis, progressed to phase 2A

-          H4R, a systemic anti-pruritic and anti-inflammatory H4 receptor antagonist for atopic dermatitis, progressed to phase 2A

-          IL-17 small molecule modulator for treatment of psoriasis moved from pre-clinical stage to phase 1

Outlook for 2022

In 2022 LEO Pharma will continue its focus on the launch of Adtralza®/Adbry™ across markets and delivering on the recently announced transformation and efficiency program which is expected to show the company delivering double-digit growth from 2023. For 2022, LEO Pharma anticipates annual revenue growth of 3-5% to DKK 10.2-10.4 billion, driven by the launch of tralokinumab and growth in our strategic products. We will continue to focus on profitability improvements for the established portfolio and to invest significantly in innovative research and development activities. Furthermore, costs related to product launches will increase significantly in 2022. LEO Pharma expects this to lead to an operating loss (EBIT) of DKK 3.1-3.3 billion in 2022.

Acting CEO of LEO Pharma, Anders Kronborg commented:

“2021 was a year dominated by transformation and progressing diligently on our strategy. While our operating result did not meet financial guidance, we are satisfied to see growth in net sales and in sales of our strategic psoriasis products Enstilar® and Kyntheum®, which both outperformed market growth. The approvals of tralokinumab in US and Europe, and filing for marketing authorization in Japan, mark other important milestones to see LEO Pharma starting to deliver increased growth and positive results from 2023 as outlined in our strategy. Also, 2021 saw LEO Pharma welcome a new Chair of the board, a new minority investor and introducing an employee share purchase program which are all proof points of the potential of the strategy we have laid out. In 2022, we will continue to invest in launching tralokinumab, accelerating our R&D efforts through our own R&D operations as well as through acquisitions and partnerships.”

Key figures

 

DKK million

2021

2020

Growth

Revenue

9,957

10,133

(2)%

Revenue adjusted for contract manufacturing business

9,570

9,122

5%

EBITDA

(1,957)

521

Operating profit (EBIT)

(4,156)

(726)

Net profit

(4,868)

(951)

R&D investments (% of revenue)

23%

21%

 

 

Annual report 2021

The full results are available in the LEO Pharma Annual Report 2021 on the company’s website at: LEO Pharma Annual Report 2021

Changes to LEO Pharma’s Board of Directors

At LEO Pharma’s Annual General Meeting 2022, Vice Chair Anders Ekblom and board member Birgitta Stymne Göransson did not stand for re-election and will leave LEO Pharma’s Board of Directors. Jesper Mailind was elected as Vice Chair by the general meeting.

Contacts

Media contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma  

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.

LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)30.10.2023 10:00:00 CET | Pressemeddelelse

Subjects who completed the 16-week twice-daily treatment regimen of delgocitinib cream or cream vehicle in the phase 3 DELTA 1 or DELTA 2 trials were offered to immediately enroll into the 36-week DELTA 3 extension trial.1 The DELTA 3 trial evaluated the long-term safety of twice-daily as needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.1 The long-term safety profile of delgocitinib cream was consistent with previous results from the DELTA 1 and 2 trials. Patients who entered the DELTA 3 trial after receiving delgocitinib cream in the DELTA 1 and DELTA 2 trials maintained similar levels of symptom relief and treatment success over an additional 36-week treatment regimen.

LEO Pharma provides update on the development program for izuforant20.10.2023 09:43:02 CEST | Pressemeddelelse

The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint. As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical. LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye